Athersys (NASDAQ:ATHX) and University Hospitals Cleveland Medical Center have opened the first clinical site for a Phase 2/3 study evaluating MultiStem cell therapy for COVID-19-induced acute respiratory distress...
Akari Therapeutics’ (NASDAQ:AKTX) nomacopan met its primary safety and secondary efficacy endpoints in a Phase 2 trial of patients with bullous pemphigoid (BP). BP is a severe orphan inflammatory skin disease...
Dova Pharmaceuticals’ (NASDAQ:DOVA) wholly-owned subsidiary, AkaRx, reported that the China National Medical Products Administration (NMPA) approved DOPTELET for the treatment of thrombocytopenia in adult patients with...
Soligenix (NASDAQ:SNGX) reported positive second cycle results for its Phase 3 trial assessing SGX301 for the treatment of cutaneous T-cell lymphoma (CTCL). The study enrolled 169 patients who were randomized to receive...
Eiger BioPharmaceuticals (NASDAQ:EIGR) dosed the first patients in its Phase 2 study of peginterferon lambda for the treatment of mild COVID-19. The study will enroll some 120 patients who will receive either a single...
Capricor Therapeutics (NASDAQ:CAPR) reported that all six critical COVID-19 patients who were treated with CAP-1002, an allogeneic cardiac cell therapy, have survived. The six COVID-19 patients, who were admitted to...
ERYTECH Pharma’s (NASDAQ:ERYP) eryaspase received FDA fast track designation for the second-line treatment of patients with metastatic pancreatic cancer. Eryaspase is being evaluated in a Phase 3 trial, called TRYbeCA...
BioXcel Therapeutics (NASDAQ:BTAI) initiated the Phase 2 efficacy portion of its Phase 1b/2 trial of BXCL701, in combination with pembrolizumab, an immunotherapy, for treatment emergent neuroendocrine prostate cancer...
Axsome Therapeutics’ (NASDAQ:AXSM) AXS-05 met its primary endpoint in a Phase 2/3 trial, called ADVANCE-1, in patients with Alzheimer’s disease (AD)-related agitation. The trial assessed 366 AD patients who were...
Avadel Pharmaceuticals (NASDAQ:AVDL) reported positive topline data from its Phase 3 trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. The Phase 3 study, called...